I'm proud to say that many years ago I sent Dr. Heather Wakelee from Stanford a set of my slides on post-operative therapy for early stage NSCLC -- we' ve been friends since we were both getting started in our careers.

Flash forward several years, and now she's among the national leaders in the field of adjuvant therapy for NSCLC and leads one of the most important trials in that setting -- the ECOG 1505 trial that is testing whether there is a benefit of adding the anti-angiogenic agent avastin (bevacizumab) to standard chemo after surgery. She was kind enough to come up from the Bay Area to participate in the GRACE NSCLC Patient Education Forum back in September to provide a brief synopsis of our understanding of the current best strategies for post-operative treatment of patients with resected NSCLC. She also did a recent podcast on the overlapping subject of clinical trials in the adjuvant setting as part of an educational grant, , but this program is a more general overview.

Here is the audio and video podcast versions of her presentation, along with transcript and figures.

[powerpress]

wakelee adjuvant nsclc overview audio

wakelee-adjuvant-nsclc-overview-transcript

wakelee-adjuvant-nsclc-overview-figures